Earnings Call · Q3 FY2025·2025-11-04

Q3 25EPS +9.09%·Rev n/aQ2 25EPS -33.33%·Rev n/aQ1 25EPS -1.59%·Rev n/aQ4 24EPS +26.44%·Rev n/a⚠ consensus missing

Tarsus Pharmaceuticals, Inc. TARS

David Nakasone — Head of Investor Relations

Bobak Azamian — President/CEO and Board Chair

Aziz Mottiwala — Chief Commercial Officer

Jeffrey S. Farrow — Chief Financial Officer

−4.6%1d on move date−5.0% vs SPY3d−4.5%5d+5.8%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TARS calls or request research access.

More TARS calls Browse calls Request research access